Wharton's jelly stromal cells as potential delivery vehicles for cancer therapeutics

Future Oncology

Volumn 5, Issue 8, 2009, Pages 1237-1244

  Rachakatla, Raja Shekar ^a   Troyer, Deryl ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

5 FU; Breast cancer; IFN ; Intratumoral; Intravenous; WJS cells

Indexed keywords

BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 6; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CELL THERAPY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LOW DRUG DOSE; LUNG TUMOR; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; STROMA CELL; TISSUE ENGINEERING; TISSUE REPAIR; UMBILICAL CORD; WHARTON JELLY STROMA CELL; XENOTRANSPLANTATION;

ANIMALS; GENE THERAPY; HUMANS; INVERTED REPEAT SEQUENCES; NEOPLASMS; STROMAL CELLS; UMBILICAL CORD;

EID: 75649095628     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.99     Document Type: Review

References (50)

1. Hambley TW, Hait WN: Is anticancer drug development heading in the right direction? Cancer Res. 69(4), 1259-1262 (2009).
2. Bianco P, Robey PG: Stem cells in tissue engineering. Nature 414(6859), 118-121 (2001).
3. Vollweiler JL, Zielske SP, Reese JS, Gerson SL: Hematopoietic stem cell gene therapy: progress toward therapeutic targets. Bone Marrow Transplant 32(1), 1-7 (2003).
4. Tlsty TD, Hein PW: Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev. 11(1), 54-59 (2001).
5. van Kempen LC, Ruiter DJ, van Muijen GN, Coussens LM: The tumor microenvironment: a critical determinant of neoplastic evolution. Eur. J. Cell Biol. 82(11), 539-548 (2003).
6. Aboody KS, Brown A, Rainov NG et al.: Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl Acad. Sci. USA 97(23), 12846-12851 (2000). ■■ The first paper to show homing of stem cells to the tumors.
7. Brown AB, Yang W, Schmidt NO et al.: Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum. Gene Ther. 14(18), 1777-1785 (2003).
8. Natsu K, Ochi M, Mochizuki Y, Hachisuka H, Yanada S, Yasunaga Y: Allogeneic bone marrow-derived mesenchymal stromal cells promote the regeneration of injured skeletal muscle without differentiation into myofibers. Tissue Eng. 10(7-8), 1093-1112 (2004).
9. Rojas M, Xu J, Woods CR et al.: Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am. J. Respir. Cell Mol. Biol. 33(2), 145-152 (2005).
10. Kim SM, Lim JY, Park SI et al.: Gene therapy using trail-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res. 68(23), 9614-9623 (2008).
11. Nakamura K, Ito Y, Kawano Y et al.: Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 11(14), 1155-1164 (2004).
12. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-b delivery into tumors. Cancer Res. 62(13), 3603-3608 (2002). ■ First demonstrated bone marrow mesenchymal stem cell (MSC) tumor tropism.
13. Studeny M, Marini FC, Dembinski JL et al.: Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl Cancer Inst. 96(21), 1593-1603 (2004).
14. Nakamizo A, Marini F, Amano T et al.: Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 65(8), 3307-3318 (2005).
15. Rachakatla RS, Marini F, Weiss ML, Tamura M, Troyer D: Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther. 14(10), 828-835 (2007). ■ First report of Wharton's jelly stromal (WJS) cell tumor homing ability and therapy.
16. Rachakatla RS, Pyle MM, Ayuzawa R et al.: Combination treatment of human umbilical cord matrix stem cell-based interferon-β gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in scid mouse lungs. Cancer Invest. 26(7), 662-670 (2008).
17. Mitchell KE, Weiss ML, Mitchell BM et al.: Matrix cells from Wharton's jelly form neurons and glia. Stem Cells 21(1), 50-60 (2003).
18. Troyer DL, Weiss ML: Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells 26(3), 591-599 (2008).
19. Karahuseyinoglu S, Cinar O, Kilic E et al.: Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells 25(2), 319-331 (2007).
20. Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE: Human umbilical cord perivascular (hucpv) cells: A source of mesenchymal progenitors. Stem Cells 23(2), 220-229 (2005).
21. Wang HS, Hung SC, Peng ST et al.: Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells 22(7), 1330-1337 (2004).
22. Weiss ML, Medicetty S, Bledsoe AR et al.: Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells 24(3), 781-792 (2006).
23. Carlin R, Davis D, Weiss M, Schultz B, Troyer D: Expression of early transcription factors oct-4, sox-2 and nanog by porcine umbilical cord (PUC) matrix cells. Reprod. Biol. Endocrinol. 4, 8 (2006).
24. Cohenuram M, Saif MW: Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP 8(1), 4-15 (2007).
25. Cho PS, Lo DP, Wikiel KJ et al.: Establishment of transplantable porcine tumor cell lines derived from MHC-inbred miniature swine. Blood 110(12), 3996-4004 (2007).
26. Weiss ML, Anderson C, Medicetty S et al.: Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells 26(11), 2865-2874 (2008).
27. Lu LL, Liu YJ, Yang SG et al.: Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 91(8), 1017-1026 (2006).
28. Lund RD, Wang S, Lu B et al.: Cells isolated from umbilical cord tissue rescue photoreceptors and visual functions in a rodent model of retinal disease. Stem Cells 25(3), 602-611 (2007).
29. Bailey MM, Wang L, Bode CJ, Mitchell KE, Detamore MS: A comparison of human umbilical cord matrix stem cells and temporomandibular joint condylar chondrocytes for tissue engineering temporomandibular joint condylar cartilage. Tissue Eng. 13(8), 2003-2010 (2007).
30. Baksh D, Yao R, Tuan RS: Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 25(6), 1384-1392 (2007).
31. Cho PS, Messina DJ, Hirsh EL et al.: Immunogenicity of umbilical cord tissue derived cells. Blood 111(1), 430-438 (2008).
32. Arnhold S, Klein H, Semkova I, Addicks K, Schraermeyer U: Neurally selected embryonic stem cells induce tumor formation after long-term survival following engraftment into the subretinal space. Invest. Ophthalmol. Vis. Sci. 45(12), 4251-4255 (2004).
33. Ishikawa T, Nakayama S, Nakagawa T et al.: Characterization of in vitro gutlike organ formed from mouse embryonic stem cells. Am. J. Physiol. Cell Physiol. 286(6), C1344-C1352 (2004).
34. Thomson JA, Marshall VS: Primate embryonic stem cells. Curr. Top. Dev. Biol. 38, 133-165 (1998).
35. Wakitani S, Takaoka K, Hattori T et al.: Embryonic stem cells injected into the mouse knee joint form teratomas and subsequently destroy the joint. Rheumatology (Oxford) 42(1), 162-165 (2003).
36. Juang SH, Wei SJ, Hung YM et al.: IFN-β induces caspase-mediated apoptosis by disrupting mitochondria in human advanced stage colon cancer cell lines. J. Interferon Cytokine Res. 24(4), 231-243 (2004).
37. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW: Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β. J. Natl Cancer Inst. 84(15), 1185-1190 (1992).
38. Wong VL, Rieman DJ, Aronson L, Dalton BJ, Greig R, Anzano MA: Growth-inhibitory activity of interferon-β against human colorectal carcinoma cell lines. Int. J. Cancer 43(3), 526-530 (1989).
39. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J: Pharmacokinetics and pharmacodynamics of IFN-β 1a in healthy volunteers. J. Interferon Cytokine Res. 20(10), 857-866 (2000).
40. Einhorn S, Grander D: Why do so many cancer patients fail to respond to interferon therapy? J. Interferon Cytokine Res. 16(4), 275-281 (1996).
41. Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A: Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J. Interferon Cytokine Res. 16(10), 759-764 (1996).
42. Klubes P, Cerna I: Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil. Cancer Res. 43(7), 3182-3186 (1983).
43. Ganta C, Chiyo D, Ayuzawa R et al.: Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. Cancer Res. 69(5), 1815-1820 (2009). ■ First report showing that stem cells may have the intrinsic ability to completely eliminate a preclinical tumor.
44. Muller A, Homey B, Soto H et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824), 50-56 (2001).
45. Arbab AS, Janic B, Knight RA et al.: Detection of migration of locally implanted ac133+ stem cells by cellular magnetic resonance imaging with histological findings. FASEB J. 22(9), 3234-3246 (2008).
46. Hall B, Dembinski J, Sasser AK, Studeny M, Andreeff M, Marini F: Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. Int. J. Hematol. 86(1), 8-16 (2007).
47. Khakoo AY, Pati S, Anderson SA et al.: Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J. Exp. Med. 203(5), 1235-1247 (2006).
48. Ayuzawa R, Doi C, Rachakatla RS et al.: Naive human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. Cancer Lett. 280(1), 31-37 (2009).
49. Mishra PJ, Humeniuk R, Medina DJ et al.: Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 68(11), 4331-4339 (2008).
50. Spaeth EL, Dembinski JL, Sasser AK et al.: Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4(4), E4992 (2009).